Evidence map›Paper›PMID 28726896›Full record

ReviewChemical Society reviews2017

Cycloaddition reactions of enoldiazo compounds.

Qing-Qing Cheng, Yongming Deng, Marianne Lankelma, Michael P Doyle

Abstract readReview
In one paragraph

Review in Chemical Society reviews, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers.

0numbers the graph read from it
0cells of the map it votes in
28citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

28 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Review
  7. Article
  8. Article
  9. Article
  10. Article
  11. B(COrganic letters · 2023
    Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Review
  17. Article
  18. Article
  19. Triarylborane-Catalyzed Alkenylation Reactions of Aryl Esters with Diazo Compounds.Angewandte Chemie (International ed. in English) · 2020
    Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Qing-Qing ChengDepartment of Chemistry, The University of Texas at San Antonio, San Antonio, Texas 78249, USA. michael.doyle@utsa.edu.
Yongming Deng
Marianne Lankelma
Michael P Doyle

Funding

CHIRAL CATALYSTS FOR ENANTIOSELECTIVE SYNTHESESR37GM046503 · NIGMS · UNIV OF MARYLAND, COLLEGE PARK · PI DOYLE, MICHAEL PATRICK · 2003 to 2012
$2.6M
CHIRAL CATALYSTS FOR ENANTIOSELECTIVE SYNTHESESR01GM046503 · NIGMS · UNIVERSITY OF ARIZONA · PI DOYLE, MICHAEL P. · 1991 to 2002
$463k
NIGMS NIH HHS R01 GM046503NIGMS NIH HHS R37 GM046503
6 · The paper itself

Abstract

Enoldiazo esters and amides have proven to be versatile reagents for cycloaddition reactions that allow highly efficient construction of various carbocycles and heterocycles. Their versatility is exemplified by (1) [2+n]-cycloadditions (n = 3, 4) by the enol silyl ether units of enoldiazo compounds with retention of the diazo functionality to furnish α-cyclic-α-diazo compounds that are themselves subject to further transformations of the diazo functional group; (2) [3+n]-cycloadditions (n = 1-5) by metallo-enolcarbenes formed by catalytic dinitrogen extrusion from enoldiazo compounds; (3) [2+n]-cycloadditions (n = 3, 4) by donor-acceptor cyclopropenes generated in situ from enoldiazo compounds that produce cyclopropane-fused ring systems. The role of dirhodium(ii) and the emergence of copper(i) catalysts are described, as are the different outcomes of reactions initiated with these catalysts. This comprehensive review on cycloaddition reactions of enoldiazo compounds, with emphasis on methodology development, mechanistic insight, and catalyst-controlled chemodivergence, aims to provide inspiration for future discoveries in the field and to catalyze the application of enoldiazo reagents by the wider synthetic community.

Identifiers

PMID28726896
PMCPMC5575991

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.